Tiotropium bromide - Generic Drug Details

What are the generic sources for tiotropium bromide and what is the scope of freedom to operate?

Tiotropium bromide is the generic ingredient in three branded drugs marketed by Boehringer Ingelheim and Lupin, and is included in three NDAs. There are five patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Tiotropium bromide has one hundred and fifteen patent family members in thirty-six countries.

There are seven drug master file entries for tiotropium bromide. Three suppliers are listed for this compound.

Summary for tiotropium bromide

International Patents:	115
US Patents:	5
Tradenames:	3
Applicants:	2
NDAs:	3
Drug Master File Entries:	7
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	74
Clinical Trials:	117
Patent Applications:	6,270
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for tiotropium bromide
What excipients (inactive ingredients) are in tiotropium bromide?	tiotropium bromide excipients list
DailyMed Link:	tiotropium bromide at DailyMed

Recent Clinical Trials for tiotropium bromide

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	PHASE1
Boehringer Ingelheim	N/A
Guangzhou Institute of Respiratory Disease	N/A

See all tiotropium bromide clinical trials

Pharmacology for tiotropium bromide

Drug Class	Anticholinergic
Mechanism of Action	Cholinergic Antagonists

Medical Subject Heading (MeSH) Categories for tiotropium bromide

Bronchodilator Agents

Cholinergic Antagonists

Parasympatholytics

Anatomical Therapeutic Chemical (ATC) Classes for tiotropium bromide

A07DA	Antipropulsives
A07D	ANTIPROPULSIVES
A07	ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
A	Alimentary tract and metabolism

N02AA	Natural opium alkaloids
N02A	OPIOIDS
N02	ANALGESICS
N	Nervous system

R03BB	Anticholinergics
R03B	OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS
R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R	Respiratory system

Paragraph IV (Patent) Challenges for TIOTROPIUM BROMIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SPIRIVA RESPIMAT	Inhalation Aerosol	tiotropium bromide	2.5 mcg per actuation	021936	1	2023-03-07
SPIRIVA	Inhalation Powder Capsules	tiotropium bromide	18 mcg	021395	1	2018-05-11

US Patents and Regulatory Information for tiotropium bromide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	SPIRIVA	tiotropium bromide	POWDER;INHALATION	021395-001	Jan 30, 2004	AB	RX	Yes	Yes	8,022,082*PED				Y
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-001	Sep 24, 2014		RX	Yes	Yes	7,837,235*PED				Y
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-001	Sep 24, 2014		RX	Yes	Yes	9,027,967*PED				Y
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-001	Sep 24, 2014		RX	Yes	Yes	7,396,341*PED				Y
Lupin	TIOTROPIUM BROMIDE	tiotropium bromide	POWDER;INHALATION	211287-001	Jun 20, 2023	AB	RX	No	No

Expired US Patents for tiotropium bromide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-002	Sep 15, 2015	6,977,042*PED
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-002	Sep 15, 2015	7,988,001*PED
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-001	Sep 24, 2014	7,104,470*PED
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-002	Sep 15, 2015	6,176,442
Boehringer Ingelheim	SPIRIVA	tiotropium bromide	POWDER;INHALATION	021395-001	Jan 30, 2004	5,478,578

International Patents for tiotropium bromide

Country	Patent Number	Title	Estimated Expiration
Colombia	5700802	DISPOSITIVO PARA SUJETAR UN ELEMENTO PARA FLUIDOS
Israel	167102	BLOCKING DEVICE FOR A SPRUNG LOCK WITH A SPRING OPERATION
Montenegro	P47108	INHALACIONI APARAT KOJI SADRŽI INHALACIONI PRAH TIOTROPIJUMA (INHALATION KIT COMPRISUNG INHALABLE POWDER OF TIOTROPIUM)
Japan	2007517646
Japan	2005525393

Supplementary Protection Certificates for tiotropium bromide

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0418716	SPC/GB02/036	United Kingdom		PRODUCT NAME: SCOPINE DI-(2-THIENYL)GLYCOLATE IN THE FORM OF THE QUATERNARY SALTS - ESPECIALLY SALTS OF TIOTROPIUM - PREFERRED TIOTROPIUMBROMIDE AND TIOTROPIUMBROMIDE MONOHYDRATE; REGISTERED: NL RVG26191 20011009; UK PL14598/0062 20020514
0418716	0290010-8	Sweden		PRODUCT NAME: TIOTROPIUM, 3BETA-(DI(2-TIENYL)HYDROXIACETOXI)-6BETA,7BETA-EPO XI-8METYL-1ALFAH,5ALFAH-TROPANIUM, ELLER ETT SALT DAERAV; NAT. REGISRTATION NO/DATE: 18094 20020503; FIRST REGISTRATION: NL RVG 26 191 20011009
0418716	300084	Netherlands		PRODUCT NAME: ZOUTEN VAN TRIOTROPIUM, IN HET BIJZONDER TIOTROPIUM BROMIDE; REGISTRATION NO/DATE: RVG 26191 20011009
0418716	05C0039	France		PRODUCT NAME: TIOTROPIUM MONOHYDRATE DE BROMURE; NAT. REGISTRATION NO/DATE: NL 31393 20050708; FIRST REGISTRATION: RVG 26191 20011009
0418716	C300084	Netherlands		PRODUCT NAME: ZOUTEN VAN TRIOTROPIUM, IN HET BIJZONDER TIOTROPIUM BROMIDE; REGISTRATION NO/DATE: RVG 26191 20011009

Tiotropium Bromide: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

What is the Current Market Size and Revenue Impact?

Tiotropium bromide is a long-acting muscarinic antagonist (LAMA) primarily used for chronic obstructive pulmonary disease (COPD) and asthma maintenance therapy. The global market for tiotropium was valued at approximately $4.2 billion in 2022, with projected compound annual growth rate (CAGR) of 5% from 2023 to 2030. Leading brands like Spiriva (by Boehringer Ingelheim) account for over 70% of the market share.

Key figures:

• 2022 Global Market: $4.2 billion
• 2030 Projected Market: $6.8 billion
• CAGR (2023-2030): 5%
• Major Brands: Spiriva (Boehringer Ingelheim), Turdoza (Novartis), and generics

What Are Major Market Drivers?

Rising Disease Prevalence

Global COPD prevalence is around 200 million cases, with an annual increase of 3.5%. The aging population in North America and Europe drives demand, as these regions comprise 60% of the inhaler therapy market.

Product Approvals and Line Extensions

Regulatory approvals of new formulations and delivery devices bolster sales. For instance, Spiriva Respimat inhaler gained approval in several markets, expanding patient access.

Generic Competition

Patent expirations in 2018 for Spiriva fostered significant generic entry. Generics now represent 20% of sales, exerting downward pressure on prices but expanding overall market volume.

Emerging Markets

Increased healthcare infrastructure investment in Asia-Pacific, Latin America, and Africa expands patient access, contributing to revenue growth.

What Market Challenges Exist?

Patent Loss and Competition

Post-patent expiries lead to margin erosion and intensified price competition, especially in low- and middle-income countries.

Pricing Pressures

Government reimbursement policies and fierce generic competition pressure profit margins, particularly in developed markets.

Patent Litigation and Legal Disputes

Legal challenges against patent extensions and exclusivity rights pose risks to market exclusivity periods, impacting revenue consistency.

What is the Financial Trajectory for Tiotropium?

Revenue Outlook

Revenue is projected to grow from $4.2 billion in 2022 to $6.8 billion in 2030, reflecting expansion in emerging markets post-patent expiry and increased adoption in developed economies.

R&D Investment Trends

Investment in next-generation inhalers and combination therapies is increasing. Major pharmaceutical companies are allocating 15-20% of their pulmonary portfolio R&D budgets to tiotropium derivatives or delivery innovations.

Pricing Strategies

Companies adopt tiered pricing based on market income levels. Patent holders maintain premium pricing till patent expiry; generics prices decline rapidly post-expiration, typically by 30-50% within two years.

Market Competition

Key competitors include glycopyrrolate and aclidinium, with market share consolidating around the leading brands. The emergence of biosimilars and inhaler device technology innovations could reshape market shares.

How Do Regulatory and Policy Changes Affect Forecasts?

Patent Laws and Data Exclusivity

Extended data exclusivity for new formulations or delivery methods can delay generic entry, extending revenue streams.

Reimbursement Policies

Coverage by national health services significantly influences sales volume. Favorable policies in the US and Europe support sustained market growth.

Approval of New Indications

Expansion of approved indications, such as COPD comorbidities, enhances market penetration, boosting revenue.

Key Market Players and Competitive Landscape

Company	Leading Drug	Market Share	Patent Status	R&D Focus
Boehringer Ingelheim	Spiriva (tiotropium bromide)	~70%	Patent expired in 2018 (patent extensions in some markets)	New delivery devices, combination therapies
Novartis	Turdoza	~10%	Patent valid through 2025	Inhaler device innovations
Mylan (now Viatris)	Generic tiotropium	~20%	Patent expired, generic market	Cost reduction strategies

Future Opportunities and Risks

Opportunities

• Expansion into emerging markets due to increasing COPD awareness and healthcare infrastructure.
• Development of combination inhalers with corticosteroids or long-acting beta-agonists to deepen market penetration.
• Innovation in inhaler design to improve drug delivery and adherence.

Risks

• Market saturation in developed economies following patent expiration.
• Price erosion from generics impacting margins.
• Regulatory delays or failures in receiving approvals for new formulations.

Key Takeaways

• The tiotropium bromide market is expected to grow driven by rising COPD prevalence, aging populations, and emerging market expansion.
• Patent expiries and increasing generic competition exert downward pressure on prices but increase sales volume.
• Companies are focusing R&D on device innovations and combination therapies to extend market relevance.
• Regulatory policies and reimbursement frameworks significantly influence revenue trajectories, especially in mature markets.
• The overall financial outlook remains positive, with a projected CAGR of 5% through 2030, albeit with margin compression in certain segments.

FAQs

1. How does patent expiration affect tiotropium bromide revenues?
Patent expiration introduces generics, leading to price reductions and revenue declines for original manufacturers but increases market access and volume.

2. What role do emerging markets play in the future of tiotropium bromide?
Emerging markets offer growth opportunities, driven by rising COPD prevalence and healthcare investments, often with less intense patent enforcement.

3. Are there new formulations of tiotropium in development?
Yes, companies are developing combination inhalers and improved delivery devices, aiming to enhance efficacy and patient adherence.

4. How do pricing strategies differ across markets?
Premium pricing persists in high-income countries until patent expiry; generic prices are substantially lower, especially in low-income regions.

5. What are the main competitive threats to current market leaders?
Generic competition, biosimilars, and technological innovations in inhaler devices threaten market shares and profit margins.

---

Sources:

1. MarketsandMarkets. (2022). COPD inhalers market forecast.
2. IQVIA. (2022). Global revenue report for inhalation therapies.
3. Boehringer Ingelheim. (2022). Spiriva product dossier.
4. German Federal Institute for Drugs and Medical Devices. (2022). Patent expiration data.
5. Global Initiative for Chronic Obstructive Lung Disease (GOLD). (2022). COPD prevalence and treatment guidelines.